Выход
Вход/Login
 
E-mail
Пароль/Password
Забыли пароль?
Введите E-mail и жмите тут. Пароль будет выслан на указанный адрес
Войти (LogIn)

 

Если вы первый раз здесь, то зарегистрируйтесь

Регистрация/Sign Up
Полное имя (Ф И О)/Full name
E-mail
Повторите E-mail
Телефон/Phone
Зарегистрироваться,
на ваш E-mail будет выслан временный пароль

Нажимая кнопку Зарегистрироваться, вы соглашаетесь с Правилами сайта и Политикой Конфиденциальности http://vidar.ru/rules.asp

 

Медицинская литература. Новинки


 

 

 

 

 

 
вce журналы << Эндокринная хирургия << 2017 год << №1 <<
стр.6
отметить
статью

Российские клинические рекомендации по диагностике и лечению высокодифференцированного рака щитовидной железы у взрослых, 2017 год

Бельцевич Д. Г., Ванушко В. Э., Румянцев П. О., Мельниченко Г. А., Кузнецов Н. С., Абросимов А. Ю., Поляков В. Г., Мудунов А. М., Подвязников С. О., Романов И. С., Поляков А. П., Слепцов И. В., Черник
Вы можете загрузить полный текст статьи в формате pdf
Бельцевич Дмитрий Германович - д.м.н., профессор, главный научный сотрудник отдела хирургии, ФГБУ “Эндокринологический научный центр” Минздрава России, belts67@gmail.com, 117036, Москва, улица Дм.Ульянова, д.11
Ванушко Владимир Эдуардович - д.м.н., главный научный сотрудник отдела хирургии, ФГБУ “Эндокринологический научный центр” Минздрава России, vanushko@gmail.com, 117036, Москва, улица Дм.Ульянова, д.11
Румянцев Павел Олегович - д.м.н., заведующий отделом радионуклидной диагностики и терапии, ФГБУ “Эндокринологический научный центр” Минздрава России, pavelrum@gmail.com, 117036, Москва, улица Дм.Ульянова, д.11
Мельниченко Галина Афанасьевна - д.м.н., профессор, академик РАН, директор Института клинической эндокринологии, ФГБУ “Эндокринологический научный центр” Минздрава России; ФГАОУ ВО “Первый Московский государственный медицинский университет им. И.М. Сеченова”, teofrast2000@mail.ru, 117036, Москва, улица Дм.Ульянова, д.11; 119992, Москва, ул. Трубецкая, д. 8, стр. 2
Кузнецов Николай Сергеевич - д.м.н., профессор, заведующий отделом эндокринной хирургии, ФГБУ “Эндокринологический научный центр” Минздрава России, kuznetsovnikolays@yandex.ru, 117036, Москва, улица Дм.Ульянова, д.11
Абросимов Александр Юрьевич - д.м.н., профессор, заведующий отделом фундаментальной патоморфологии, ФГБУ “Эндокринологический научный центр” Минздрава России, nikitarusskikh@mail.ru, 117036, Москва, улица Дм.Ульянова, д.11
Поляков Владимир Георгиевич - д.м.н., профессор, академик РАН, заместитель директора по научной работе НИИ детской онкологии и гематологии, ФГБУ “Российский онкологический научный центр им. Н.Н. Блохина” Минздрава России, vgp-04@mail.ru, 115478, г. Москва, Каширское шоссе, 24
Мудунов Али Мурадович - д.м.н., заведующий отделом опухолей головы и шеи, ФГБУ “Российский онкологический научный центр им. Н.Н. Блохина” Минздрава России, ali.mudunov@info.ru, 115478, г. Москва, Каширское шоссе, 24
Подвязников Сергей Олегович - д.м.н., профессор кафедры

В представленных клинических рекомендациях обсуждаются современные подходы к диагностике и лечению дифференцированного рака щитовидной железы у взрослых. Изменения в настоящей редакции Клинических рекомендаций касаются показаний к пункционной биопсии, скринингового определения концентрации кальцитонина, унификации заключений цитологического исследования, новых подходах к послеоперационной динамической стратификации риска рецидива, показаний к супрессивной и заместительной терапии, таргетной терапии йоднегативных форм дифференцированного рака щитовидной железы.

Ключевые слова:
дифференцированный рак щитовидной железы, ДРЩЖ, тонкоигольная аспирационная биопсия, ТАБ, скрининг, кальцитонин, цитология, супрессивная терапия, заместительная терапия, таргетная терапия, радиойод-резистентность, differentiated thyroid cancer, fine-needle aspiration, FNAB, FNA, screening, calcitonin, cytology, suppressive therapy, thyroid replacement therapy, targeted therapy, radioactive iodine-

Литература:
1.1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid.2015;26(1):1-133. doi: 10.1089/thy.2015.0020.
2.2. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid.2009;19(11):1167-1214. doi: 10.1089/thy.2009.0110.
3.3. Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid. 2006;16:181-186. doi: 10.1089/thy.2006.16.181.
4.4. Capezzone M, Marchisotta S, Cantara S, et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer. 2008;15(4):1075-1081. doi: 10.1677/ERC-08-0080.
5.5. Moses W, Weng J, Kebebew E. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid. 2011;21(4):367-371. doi: 10.1089/thy.2010.0256.
6.6. Ito Y, Kakudo K, Hirokawa M, et al. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery. 2009;145(1):100-105. doi: 10.1016/j.surg.2008.08.004.
7.7. Park YJ, Ahn HY, Choi HS, et al. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. Thyroid. 2012;22(4):356-362. doi: 10.1089/thy.2011.0163.
8.8. Mazeh H, Benavidez J, Poehls JL, et al. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid. 2012;22(1):3-8. doi: 10.1089/thy.2011.0192.
9.9. Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, et al. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study. Thyroid. 2011;21(1):43-48. doi: 10.1089/thy.2009.0406.
10.10. Richards ML. Familial syndromes associated with thyroid cancer in the era of personalized medicine. Thyroid. 2010;20(7):707-713. doi: 10.1089/thy.2010.1641.
11.11. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89(1):163-168. doi: 10.1210/jc.2003-030550.
12.12. Hahm JR, Lee MS, Min YK, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid. 2001;11(1):73-80. doi: 10.1089/10507250150500694.
13.13. Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab. 1997;82:338-341. doi: 10.1210/jcem.82.2.3737.
14.14. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92(2):450-455. doi: 10.1210/jc.2006-1590.
15.15. Chambon G, Alovisetti C, Idoux-Louche C, et al. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients. J Clin Endocrinol Metab. 2011;96(1):75-81. doi: 10.1210/jc.2010-0162.
16.16. Абдулхабирова Ф.М., Бельцевич Д.Г., Ванушко В.Э., и др. Диагностика и лечение медуллярного рака щитовидной железы (проект национальных клинических рекомендаций). // Эндокринная хирургия. - 2012. - Т. 6. - №1 - С. 5-17. doi: 10.14341/2306-3513-2012-1-5-17.
17.17. Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008;150(1):49-52. doi: 10.1016/j.jss.2007.09.020.
18.18. Suh I, Vriens MR, Guerrero MA, et al. Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid. Am J Surg. 2010;200(1):41-46. doi: 10.1016/j.amjsurg.2009.08.030.
19.19. Lee EK, Chung KW, Min HS, et al. Preoperative serum thyroglobulin as a useful predictive marker to differentiate follicular thyroid cancer from benign nodules in indeterminate nodules. J Korean Med Sci. 2012;27(9):1014-1018. doi: 10.3346/jkms.2012.27.9.1014.
20.20. Smith-Bindman R, Lebda P, Feldstein VA, et al. Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study. JAMA Intern Med. 2013;173(19):1788-1796. doi: 10.1001/jamainternmed.2013.9245.
21.21. Brito JP, Gionfriddo MR, Al Nofal A, et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(4):1253-1263. doi: 10.1210/jc.2013-2928.
22.22. Langer JE, Agarwal R, Zhuang H, et al. Correlation of findings from iodine 123 scan and ultrasonography in the recommendation for thyroid fine needle aspiration biopsy. Endocr Pract. 2011;17(5):699-706. doi: 10.4158/EP10382.OR.
23.23. Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology. 2011;260(3):892-899. doi: 10.1148/radiol.11110206.
24.24. Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation -multicenter retrospective study. Radiology. 2008;247(3):762-770. doi: 10.1148/radiol.2473070944.
25.25. Moon HJ, Kwak JY, Kim MJ, et al. Can vascularity at power Doppler US help predict thyroid malignancy? Radiology. 2010;255(1):260-269. doi: 10.1148/radiol.09091284.
26.26. Salmaslioglu A, Erbil Y, Dural C, et al. Predictive value of sonographic features in preoperative evaluation of malignant thyroid nodules in a multinodular goiter. World J Surg. 2008;32(9):1948-1954. doi: 10.1007/s00268-008-9600-2.
27.27. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87(5):1941-1946. doi: 10.1210/jcem.87.5.8504.
28.28. Gul K, Ersoy R, Dirikoc A, et al. Ultrasonographic evaluation of thyroid nodules: comparison of ultrasonographic, cytological, and histopathological findings. Endocrine. 2009;36(3):464-472. doi: 10.1007/s12020-009-9262-3.
29.29. Cappelli C, Pirola I, Cumetti D, et al. Is the anteroposterior and transverse diameter ratio of nonpalpable thyroid nodules a sonographic criteria for recommending fine-needle aspiration cytology? Clin Endocrinol (Oxf). 2005;63(6):689-693. doi: 10.1111/j.1365-2265.2005.02406.x.
30.30. Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006;91(9):3411-3417. doi: 10.1210/jc.2006-0690.
31.31. Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab. 2009;94(5):1748-1751. doi: 10.1210/c.2008-1724.
32.32. Tae HJ, Lim DJ, Baek KH, et al. Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules. Thyroid. 2007;17(5):461-466. doi: 10.1089/thy.2006.0337.
33.33. Shimura H, Haraguchi K, Hiejima Y, et al. Distinct diagnostic criteria for ultrasonographic examination of papillary thyroid carcinoma: a multicenter study. Thyroid. 2005;15(3):251-258. doi: 10.1089/thy.2005.15.251.
34.34. Russ G, Royer B, Bigorgne C, et al. Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography. Eur J Endocrinol. 2013;168(5):649-655. doi: 10.1530/EJE-12-0936.
35.35. Cheng SP, Lee JJ, Lin JL, et al. Characterization of thyroid nodules using the proposed thyroid imaging reporting and data system (TIRADS). Head Neck. 2013;35(4):541-547. doi: 10.1002/hed.22985.
36.36. Ito Y, Amino N, Yokozawa T, et al. Ultrasonographic evaluation of thyroid nodules in 900 patients: comparison among ultrasonographic, cytological, and histological findings. Thyroid. 2007;17(12):1269-1276. doi: 10.1089/thy.2007.0014.
37.37. Ito Y, Miyauchi A, Kihara M, et al. 2014 Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24(1):27-34. doi: 10.1089/thy.2013.0367.
38.38. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36(6):425-437. doi: 10.1002/dc.20830.
39.39. Crippa S, Mazzucchelli L, Cibas ES, et al. The Bethesda System for reporting thyroid fine-needle aspiration specimens. Am J Clin Pathol. 2010;134(2):343-344. doi: 10.1309/ajcpxm9wirq8jzbj.
40.40. Na DG, Kim JH, Sung JY, et al. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda System for reporting thyroid cytopathology. Thyroid. 2012;22(5):468-475. doi: 10.1089/thy.2011.0185.
41.41. Nam SY, Han BK, Ko EY, et al. BRAFV600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis. Thyroid. 2010;20(3):273-279. doi: 10.1089/thy.2009.0226.
42.42. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146(6):1215-1223. doi: 10.1016/j.surg.2009.09.011.
43.43. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95(3):1365-1369. doi: 10.1210/jc.2009-2103.
44.44. Renshaw AA, Pinnar N. Comparison of thyroid fine-needle aspiration and core needle biopsy. Am J Clin Pathol. 2007;128(3):370-374. doi: 10.1309/07TL3V58337TXHMC.
45.45. Yeon JS, Baek JH, Lim HK, et al. Thyroid nodules with initially nondiagnostic cytologic results: the role of core-needle biopsy. Radiology. 2013;268(1):274-280. doi: 10.1148/radiol.13122247.
46.46. Ahn JE, Lee JH, Yi JS, et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg. 2008;32(7):1552-1558. doi: 10.1007/s00268-008-9588-7.
47.47. Choi JS, Kim J, Kwak JY, et al. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol. 2009;193(3):871-878. doi: 10.2214/AJR.09.2386.
48.48. Lesnik D, Cunnane ME, Zurakowski D, et al. Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. Head Neck. 2014;36(2):191-202. doi: 10.1002/hed.23277.
49.49. Jeong HS, Baek CH, Son YI, et al. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf). 2006;65(3):402-407. doi: 10.1111/j.1365-2265.2006.02612.x.
50.50. Kaplan SL, Mandel SJ, Muller R, et al. The role of MR imaging in detecting nodal disease in thyroidectomy patients with rising thyroglobulin levels. AJNR Am J Neuroradiol. 2009;30(3):608-661. doi: 10.3174/ajnr.A1405.
51.51. Andersen PE, Kinsella J, Loree TR, et al. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg. 1995;170(5):467-470. doi: 10.1016/S0002-9610(99)80331-6.
52.52. Kim E, Park JS, Son KR, et al. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid. 2008;18(4):411-418. doi: 10.1089/thy.2007.0269.
53.53. Yeh MW, Bauer AJ, Bernet VA, et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid. 2015;25(1):3-14. doi: 10.1089/thy.2014.0096.
54.54. Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228(3):320-330. doi: 10.1097/00000658-199809000-00005.
55.55. Loyo M, Tufano RP, Gourin CG. National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope. 2013;123(8):2056-2063. doi: 10.1002/lary.23923.
56.56. Gourin CG, Tufano RP, Forastiere AA, et al. Volume-based trends in thyroid surgery. Arch Otolaryngol Head Neck Surg. 2010;136(12):1191-1198. doi: 10.1001/archoto.2010.212.
57.57. Stavrakis AI, Ituarte PH, Ko CY, et al. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery. 2007;142(6):887-899. doi: 10.1016/j.surg.2007.09.003.
58.58. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246(3):375-381. doi: 10.1097/SLA.0b013e31814697d9.
59.59. Grant CS, Hay ID, Gough IR, et al. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery. 1988;104(6):954-962.
60.60. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124(6):958-964. doi: 10.1016/S0039-6060(98)70035-2.
61.61. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447-1463. doi: 10.1210/jcem.86.4.7407.
62.62. Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38(1):68-79. doi: 10.1007/s00268-013-2224-1.
63.63. Barney BM, Hitchcock YJ, Sharma P, et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011;33(5):645-649. doi: 10.1002/hed.21504.
64.64. Mendelsohn AH, Elashoff DA, Abemayor E, et al. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136(11):1055-1061. doi: 10.1001/archoto.2010.181.
65.65. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in lowor high-risk papillary thyroid cancer. Ann Surg Oncol. 2005;12(1):81-89. doi: 10.1007/s10434-004-1165-1.
66.66. Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012;151(4):571-579. doi: 10.1016/j.surg.2011.08.016.
67.67. Adam MA, Pura J, Gu L et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260(4):601-605. doi: 10.1097/SLA.0000000000000925.
68.68. Vaisman F, Shaha A, Fish S, et al. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf).2011;75(1):112-119. doi: 10.1111/j.1365-2265.2011.04002.x.
69.69. Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141(5):489-494. doi: 10.1001/archsurg.141.5.489.
70.70. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134(6):946-954. doi: 10.1016/S0039-6060(03)00424-0.
71.71. Hughes DT, White ML, Miller BS, et al. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery. 2010;48(6):1100-1106. doi: 10.1016/j.surg.2010.09.019.
72.72. Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144-1152. doi: 10.1089/thy.2012.0043.
73.73. Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144(6):1070-1077. doi: 10.1016/j.surg.2008.08.034.
74.74. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90(10):5723-5729. doi: 10.1210/jc.2005-0285.
75.75. Sugitani I, Kasai N, Fujimoto Y, et al. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135(2):139-148. doi: 10.1016/S0039-6060(03)00384-2.
76.76. Robbins KT, Shaha AR, Medina JE, et al. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. 2008;134(5):536-538. doi: 10.1001/archotol.134.5.536.
77.77. Hwang HS, Orloff LA. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. Laryngoscope. 2011;121(3):487-491. doi: 10.1002/lary.21227.
78.78. Mulla M, Schulte KM. Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment. Clin Endocrinol (Oxf). 2012;76(1):131-136. doi: 10.1111/j.1365-2265.2011.04162.x.
79.79. Hartl DM, Leboulleux S, Al Ghuzlan A, et al. Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg. 2012;255(4):777-783. doi: 10.1097/SLA.0b013e31824b7b68.
80.80. Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery. 2011;150(6):1048-1057. doi: 10.1016/j.surg.2011.09.003.
81.81. Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope. 2009;119(6):1135-1139. doi: 10.1002/lary.20236.
82.82. Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab. 2009;94(4):1162-1167. doi: 10.1210/jc.2008-1931.
83.83. Sancho JJ, Lennard TW, Paunovic I, et al. Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014;399(2):155-163. doi: 10.1007/s00423-013-1152-8.
84.84. Zetoune T, Keutgen X, Buitrago D, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol. 2010;17(12):3287-3293. doi: 10.1245/s10434-010-1137-6.
85.85. Barczynski M, Konturek A, Stopa M, et al. Prophylactic central neck dissection for papillary thyroid cancer. Br J Surg.

2017 Russian clinical practice guidelines for differentiated thyroid cancer diagnosis and treatment

Beltsevich D. G., Vanushko V. E., Rumiantsev P. O., Melnichenko G. A., Kuznetsov N. S., Abrosimov A. Y., Polyakov V. G., Mudunov A. M., Podvyaznikov S. O., Romanov I. S., Polyakov A. P., Sleptsov I. V

The Russian clinical practice guidelines for diagnosis and treatment of differentiated thyroid cancer is dedicated to the management of patients with differentiated thyroid cancer. The guideline modifications 2016 include the following matters: indication for fine-needle aspiration biopsy, calcitonin screening, standards for biopsy results, new positions of postoperative risk stratification, indication for suppressive therapy and thyroid replacement therapy, targeted therapy in patients with radioiodine-refractory differentiated thyroid cancer.

Keywords:
дифференцированный рак щитовидной железы, ДРЩЖ, тонкоигольная аспирационная биопсия, ТАБ, скрининг, кальцитонин, цитология, супрессивная терапия, заместительная терапия, таргетная терапия, радиойод-резистентность, differentiated thyroid cancer, fine-needle aspiration, FNAB, FNA, screening, calcitonin, cytology, suppressive therapy, thyroid replacement therapy, targeted therapy, radioactive iodine-

Новости   Магазин   Журналы   Контакты   Правила   Доставка   О компании  
ООО Издательский дом ВИДАР-М, 2024